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and effectiveness of vaccines in HIV-infected and HIV-exposed children as outcomes.
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Abstract 31 
Evidence-based approaches were used in making recommendations for vaccination against 32 
vaccine-preventable diseases for HIV-infected and HIV-exposed individuals but with limited 33 
substantiation. We conducted a systematic review and meta-analysis with randomised-controlled 34 
trials (RCTs), cohort and case-control studies that have efficacy and effectiveness of vaccines in 35 
HIV-infected and HIV-exposed children as outcomes. Web of Science, Cochrane Library, PubMed 36 
and Scopus databases were searched for articles. Efficacy of 9-valent pneumococcal conjugate 37 
vaccine (PCV9) against total vaccine serotype invasive pneumococcal disease was 32% in HIV-38 
infected children and 78% among HIV-uninfected children. Vaccine effectiveness of Bacillus 39 
Calmette–Guérin vaccine in preventing tuberculosis in HIV-infected children was zero compared 40 
to 59% protection in HIV-unexposed children. Likewise, HIV-uninfected children have better 41 
protection against invasive Haemophilis influenzae type b disease than the HIV-infected children. 42 
Effectiveness studies of rotavirus vaccines show that HIV-exposed uninfected children have 43 
similar protection against rotavirus gastroenteritis compared to the non-exposed children. Children 44 
who are severely immunosuppressed are poorly protected against invasive pneumococcal diseases. 45 
HIV-infected children tend to have lesser vaccine protection against vaccine-preventable diseases 46 
when compared to unexposed children. HIV-infected children who are immunocompetent are 47 
more likely to have better vaccine protection against vaccine-preventable diseases than those who 48 
are immunosuppressed. The overall quality of the observational studies was very low with very 49 
little confidence in the effect estimate. The overall quality of evidence for the RCT outcomes was 50 
mainly high. This study reveals a dearth of efficacy and effectiveness studies among HIV-infected 51 
and exposed children. 52 
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; efficacy; effectiveness 53 
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Background 58 
Immunisation is an essential aspect of preventive medicine and critical in reducing morbidity and 59 
mortality attributed to vaccine-preventable diseases in children, adolescents and adults.1 The use 60 
of vaccines against various vaccine-preventable diseases is beneficial and an effective measure for 61 
protecting different age groups.2,3 The vaccination rates of children remain insufficient for vaccine-62 
preventable diseases in many developing countries with only 86% of infants vaccinated with three 63 
doses of diphtheria-tetanus-pertussis containing vaccine in 2016.4 Low vaccination uptake rate 64 
results in an increase in unvaccinated and under-vaccinated human immunodeficiency virus 65 
(HIV)-infected and HIV-exposed children who are more likely to die from preventable diseases 66 
than their immunocompetent age mates.5,6 Several care and treatment guidelines have identified 67 
vaccination as a crucial preventive strategy for people living with HIV7,8 but information on the 68 
use of certain vaccines in this population are still scanty.9  69 
Experts using evidenced-based approaches on the vaccination of immunocompromised individuals 70 
made specific recommendations for vaccination against major vaccine-preventable diseases for 71 
these patients but with limited proof.8 Research gaps were also identified by this group for future 72 
investigation. One of these gaps was that of understanding the mediators of vaccine protection, 73 
adverse effects and basic aspects of the epidemiology of various vaccine-preventable diseases.8  74 
Vaccines stimulate immunity that protects against specific disease-causing organisms. However, 75 
the effectiveness of different recommended vaccines in HIV-infected children may be reduced as 76 
a result of the decline in vaccine-induced antibodies.10 The changing pattern of some vaccine-77 
preventable diseases is poorly understood, and this changing pattern and epidemiology makes it 78 
important to better understand these diseases because of apparent resurgence and epidemics in 79 
future.11 The suboptimal uptake of vaccines in sub-Saharan Africa coupled with the high HIV 80 
burden are risk factors that may facilitate future epidemics.11,12  81 
Previous reviews on the efficacy and effectiveness of vaccines in HIV-infected and exposed 82 
children were not specific on the vaccine efficacy/effectiveness against disease outcomes and were 83 
not conducted as systematic reviews 13,14. It is paramount to evaluate the available evidence by 84 
identifying high-quality literature and investigating the reliability of key findings as they relate to 85 
the pre-licensure efficacy and post-licensure effectiveness of vaccines in HIV-infected and HIV-86 
exposed children compared to HIV unexposed children. The findings will provide the needed 87 
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evidence to guide healthcare policymakers, guideline developers, vaccinologists and healthcare 88 
workers in developing improved long-term vaccination strategies for HIV-infected children. 89 
Current and reliable evidence-based data on the efficacy and effectiveness of vaccines in HIV-90 
infected and HIV-exposed children are also vital to inform a better understanding of the prevention 91 
and management of vaccine-preventable diseases in these children.  92 
This systematic review and meta-analysis summarised available data from studies which have 93 
efficacy or effectiveness of vaccines in HIV-infected and HIV-exposed children as outcomes. 94 
 95 
Results 96 
Description of included studies 97 
The flow diagram in Figure 1 shows the studies identified and selected for this review. We 98 
identified 725 publications through databases and clinical trial registry search with 479 studies 99 
after removal of duplicates. A total of 14 publications were included in this review. These 100 
publications comprise five randomised-controlled trials (RCTs),15-19 six case-control studies,20-25 101 
one cohort study26 and two cross-sectional studies27,28. Three of the included studies were 102 
publications from a particular South African trial that reported different vaccine efficacy 103 
outcomes.15,17,18 The included studies were published from 1993 to 2017.  All the included studies 104 
were conducted in sub-Saharan Africa with ten publications from South Africa, one each from 105 
Malawi, Angola and Zambia, and one multinational study conducted in Mali, Kenya and Ghana.  106 
By outcomes, three studies reported rotavirus vaccine outcomes, six studies reported on 107 
pneumococcal vaccine, one study reported on Hib vaccine, two studies on Bacillus Calmette–108 
Guérin (BCG) and two studies reported on Hepatitis B virus (HBV) vaccines (Table 1). Two 109 
studies compared vaccine strains with placebo among HIV-infected children while three studies 110 
compared vaccine strains with placebo among HIV-infected and HIV-unexposed children. Six 111 
studies compared HIV-infected children with HIV-unexposed children, while two studies 112 
compared HIV-exposed and uninfected children with HIV-unexposed children. In total, 66,220 113 
children in comparative studies were involved in the included studies. The vaccine schedule and 114 
doses for the included studies were according to various national programme except for Madhi 115 
200717 participants who were followed up for five years. Antiretroviral therapy (ART) usage 116 
varied between 22.5% and 67.0% among the HIV-infected children.  117 
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Figure 1: Flow diagram of the search and selection process for this review 118 
 119 
Table 1: Characteristics of included studies 120 
 121 
 122 
Quality of evidence 123 
 124 
Risk of bias assessment of individual studies                                                                                                                            125 
Risk of bias assessment of the included studies is summarised separately for RCTs (Figure 2) 126 
and observational studies (Figure 3). All the studies except one contained at least one domain 127 
classified as high risk of bias or with no clear information.  128 
Randomised trials 129 
Only three RCTs were assessed.15,16,19 Klugman 200315 was used in assessing two other included 130 
studies17,18 since the study participants were the same for all three publications. There was 131 
insufficient information on random sequence selection in majority of the studies as shown in 132 
Figure 4. Allocation concealment, performance and detection biases were low for most of the 133 
studies. Steele 201119 had unclear risk of bias for most of the domains. Feikin 201216 had high risk 134 
of bias for reporting and other bias domains for not reporting all the pre-specified primary 135 
outcomes and having numerous limitations.  136 
 137 
 138 
Figure 2: Risk of bias summary for the included randomised-controlled trials 139 
 140 
Observational studies 141 
All the observational studies had one high or unclear risk of bias across different domains except 142 
one study.15,20,21,23-28 The reasons for the high risk of bias varied and ranged from the use of hospital 143 
control instead of community controls, imbalanced missing participant numbers and unmeasured 144 
confounders (Figure 5).  145 
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 148 
  Figure 3: Risk of bias summary for the included observational studies 149 
 150 
Figure 4: Risk-of-bias graph: review authors' judgements about each risk-of-bias item presented as percentages 151 
across all included studies 152 
 153 
Figure 5: Risk of bias graph: review authors' judgements about each risk-of-bias item presented as percentages 154 
across all included studies 155 
 156 
The quality of the evidence was also evaluated using the Grades of Recommendations, 157 
Assessment, Development and Evaluation (GRADE) approach. Overall quality for the 158 
observational studies was very low with very little confidence in the effect estimate. The overall 159 
quality of evidence for the RCT outcomes was mainly high. This makes our confidence in the 160 
effect estimate to be moderate. With these results, we are confident that the true effect lies close 161 
to that of the estimate of the effect and does not require further research. See Summary of findings 162 
in Tables 2 and 3. 163 
Table 2: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-164 
uninfected children (RCTs) 165 
 166 
Table 3: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-167 
uninfected children (Observational studies) 168 
 169 
Vaccine efficacy for vaccine-preventable diseases outcomes 170 
Table 4 shows reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes 171 
in vaccinated versus non-vaccinated participants in trials for several outcomes. Vaccine efficacy 172 
of 9-valent pneumococcal conjugate vaccine (PCV9) vs. placebo in preventing first episodes of 173 
invasive pneumococcal disease was 53% (95% CI 21 - 73) among HIV-infected children and 42% 174 
(95% CI -28 - 75) among HIV-uninfected children. Efficacy of PCV9 against total vaccine 175 
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serotype invasive pneumococcal disease was 32% (95% CI -14 - 60) in HIV-infected and 78% 176 
(95% CI 34 - 92) among HIV-uninfected children.  177 
There was similar response among HIV-infected children who were given RIX4414 vaccine and 178 
those given placebo for prevention of acute rotavirus diarrhoea (RR= 1.00; 95% CI 0.26 - 3.78) 179 
(Table 5). The subset of HIV-infected children in a particular trial that compared pentavalent 180 
rotavirus vaccine (PRV) and placebo showed RR of 2.81 (95% CI 0.12 - 63.83) (Table 5). 181 
Vaccine effectiveness for vaccine-preventable diseases outcomes 182 
Table 6 reports vaccine effectiveness for vaccine-preventable diseases outcomes in vaccinated 183 
versus non-vaccinated participants in observational studies for different outcomes. The pooled 184 
odds ratio (OR) of two studies on the effectiveness of HBV vaccines between HIV-infected and 185 
HIV-uninfected children was OR = 6.02 (95% CI 0.93 - 38.83; I2 = 0.00%) (Table 5; Figure 6). 186 
Vaccine effectiveness of BCG vaccine in preventing tuberculosis in HIV-infected children was 187 
zero compared to 59% protection in HIV-unexposed children (Table 5). Likewise, HIV-uninfected 188 
children have better protection against invasive Hib disease than the HIV-infected children (97% 189 
versus 44%). Effectiveness studies of rotavirus vaccines show that HIV-exposed uninfected 190 
children have similar protection against rotavirus gastroenteritis comparable to the non-exposed 191 
children. The adjusted vaccine effectiveness of PCV13 against invasive pneumococcal disease was 192 
78% (95% CI 46 to 91) in HIV-uninfected children, 17% (95% CI –304 - 80) in HIV-infected and 193 
–104% (95% CI –1433 - 73) among HIV-infected children who were severely immunosuppressed. 194 
 195 
Figure: 6: Forest plot of comparison: Vaccine effectiveness comparing HIV-infected and HIV-uninfected - 196 
Hepatitis B vaccine, outcome: HBV/Hepatitis B vaccine 197 
 198 
Table 4: Reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes in vaccinated vs. 199 
non-vaccinated participants in randomised-controlled trials 200 
 201 
Table 5: Calculated vaccine efficacy and effectiveness for various vaccine outcomes 202 
Table 6: Reported vaccine effectiveness against vaccine-preventable diseases in observational studies 203 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Discussion 204 
The findings of this systematic review show that various routine vaccines have varying levels 205 
of protective efficacy and effectiveness against different vaccine-preventable diseases among 206 
HIV-infected and HIV-exposed children. This study demonstrates that PCV9 and 13-valent 207 
pneumococcal conjugate vaccine (PCV13) vaccines are efficacious in preventing invasive 208 
pneumococcal disease, radiologically confirmed pneumonia and severe pneumonia.15 PCV9 209 
also reduced the incidence of antibiotic-resistant invasive and vaccine serotype pneumococcal 210 
disease in both HIV-infected and uninfected children.15 However, PCV vaccines are less 211 
efficacious in preventing total vaccine serotype invasive pneumococcal disease in HIV-212 
infected children compared to HIV-uninfected children.16 Cohen et al. show that HIV-infected 213 
children have less protection against invasive pneumococcal disease when vaccinated with 214 
doses of PCV13.21 HIV-infected children with severe immunosuppression are unprotected 215 
against invasive pneumococcal disease even at higher vaccine doses.21 216 
Vaccine-efficacy studies show that RIX4414 and PRV do not have protective activities against 217 
acute rotavirus diarrhoea in HIV-infected children.16,19 The poor efficacy of PRV in children 218 
living with HIV may largely be as a result of the small sample size of the HIV-infected children 219 
subset in a Kenyan trial.16 However, Feikin et al. show that PRV efficacy against severe 220 
rotavirus gastroenteritis was 63.9% (95% CI −5.9-89.8) in a study with a large number of both 221 
HIV-infected and uninfected children in the second year of life and 83% in the first year of life. 222 
The study on RIX4414 shows that there was no significant difference in the incidence of 223 
rotavirus diarrhoea in the vaccine and placebo groups thereby deducing that the vaccine did 224 
not have any significant protective effect in HIV-infected children.17 Monovalent rotavirus 225 
vaccines provided at least 40-60% protection against acute rotavirus gastroenteritis in both 226 
HIV-exposed uninfected and HIV-unexposed children but the effectiveness in HIV-infected 227 
children is not yet known.23,26  228 
Vaccine-effectiveness studies show that Hib conjugate vaccine provided more than 50% 229 
protection against invasive Hib disease in HIV-uninfected children when compared to HIV-230 
infected children.24 Hib conjugate vaccine has a protective effect of 83% in preventing overall 231 
invasive Hib disease in among HIV-infected children and very useful.26 A study among 232 
Zambian children shows that BCG has 59% protective effect against tuberculosis in HIV-233 
uninfected children and none in HIV-infected children.24 The findings of a case-control study 234 
among Brazilian children also allude to the fact that BCG does not protect against tuberculosis 235 
in immunodeficient HIV-infected children.20 236 
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Studies have shown that most of the vaccines included in this review are safe for use in all 237 
categories of children.1,15,19,29,30 A number of reviews and safety studies on several routine 238 
vaccines among HIV-infected/exposed children and HIV-unexposed children show that there 239 
was no significant difference in these groups of children with respect to adverse events, serious 240 
adverse events and death.26-33 Most of the serious adverse events and deaths were not vaccine 241 
related. Reviews also show that immune responses to primary vaccination in HIV-infected 242 
children were less likely compared to HIV-unexposed and HIV-exposed children and may 243 
require booster doses.31-33  244 
There is a dearth of vaccine efficacy and effectiveness studies against vaccine-preventable 245 
diseases among HIV-infected and exposed children. This review shows that some efficacy 246 
studies have been done for PCV, BCG, rotavirus vaccines and Hib vaccines in HIV-infected 247 
children. There is a need to close the knowledge gap in relation to pre-licensure vaccine 248 
efficacy and post-licensure vaccine effectiveness against key vaccine-preventable diseases 249 
among these groups of children. Closing the gaps will entail conducting efficacy and 250 
effectiveness studies for several routine vaccines in HIV-infected and exposed children.13 Use 251 
of BCG vaccines in HIV-infected children can lead to disseminated tuberculosis hence it is 252 
contraindicated in immunocompromised children. It is therefore, not advisable to do a BCG 253 
vaccine-efficacy study in these children.34 BCG is safe in immunocompetent infants, however, 254 
immunocompromised infants are at high risk of developing disseminated BCG disease.35  255 
It is estimated that 1.8M children are currently with living with HIV,  most of them residing in 256 
sub-Saharan Africa.36 This region also has the highest burden for most of the vaccine–257 
preventable diseases such as tuberculosis etc.37 It is therefore essential to have the children 258 
living with HIV and those exposed to HIV be protected against vaccine-preventable diseases 259 
despite possible lower vaccine efficacy among such populations.  260 
Effectiveness research is essential and relevant for decision making by policy makers, 261 
treatment guideline researchers, vaccine development researchers and healthcare providers.38 262 
Vaccine-efficacy research is essential in making the necessary decisions to achieve the goals 263 
of the Global Health 2035 Grand Convergence.39 The World Health Organization (WHO) has 264 
already recommended many vaccines for use in immunocompromised children especially those 265 
who have had exposure to HIV, however, most of these recommendations were made without 266 
specific vaccine-efficacy and effectiveness studies conducted in this population but rather from 267 
research findings on immunocompetent children or by using safety and immunogenicity 268 
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studies.1,34  Advisory Committee on Immunization Practices (ACIP) also recommended various 269 
licensed vaccines for HIV-exposed children from birth through adolescence years except for 270 
BCG.40  Knowing the vaccine efficacy and effectiveness against specific diseases will help 271 
steer guideline development and the need for better vaccines if the level of protection is low. 272 
Strengths of this systematic review and meta-analysis are the comprehensive search conducted 273 
in several databases and the inclusion of several routine vaccines. This review also compiled 274 
evidence on efficacy and effectiveness of vaccines that could be of use in HIV-infected and 275 
HIV-exposed children especially in sub-Saharan Africa. The outcomes reported and pooled for 276 
this review were based on clinical features and diagnostic methods that has not changed 277 
significantly over the last two decades and as such not a limitation for this study. Lack of direct 278 
comparisons between HIV-infected and unexposed children with respect to various clinical 279 
cases of vaccine-preventable diseases limited straightforward grading of the evidence for 280 
clinical case outcomes.   Only seven studies could be included in the meta-analysis due to lack 281 
of data information on some clinical outcomes and reported efficacy and effectiveness as 282 
described by the authors. Most of the included papers did not relate the immune status of the 283 
children with the efficacy of the administered vaccines except for Cohen et al. 21 which shows 284 
that lesser efficacy in children with severe immunosuppression. The included studies also did 285 
not report on the time interval between vaccination and the onset of the vaccine-preventable 286 
diseases.  287 
 288 
Conclusions 289 
Efficacy and effectiveness studies on vaccination exhibit possibilities for direct and indirect 290 
protection against various vaccine-preventable diseases among HIV-infected and HIV-exposed 291 
children. HIV-infected children tend to have less protection against vaccine-preventable 292 
diseases when compared to unexposed children. HIV-infected children who are 293 
immunocompetent are more likely to have better vaccine protection against vaccine-294 
preventable diseases than the immunosuppressed ones. There is also a need to bridge the 295 
knowledge gap on vaccine efficacy and effectiveness of several routine vaccines in HIV-296 
infected and exposed children. The study suggests that only a few vaccine-efficacy and 297 
effectiveness studies have been done in HIV-infected and exposed children previously. 298 
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Methods 300 
Search strategy and selection criteria 301 
This review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis 302 
Protocols (PRISMA) guideline.41 The review was registered with PROSPERO (International 303 
prospective register of systematic reviews) (CRD42018095334).  304 
 305 
Eligibility criteria 306 
 307 
Inclusion criteria 308 
 309 
We included randomised-controlled trials, cohort and case-control studies that included 310 
efficacy or effectiveness of vaccines in HIV-infected in comparison with HIV-exposed or HIV-311 
uninfected children aged ≤ 18 years. The intervention group included those with standard 312 
vaccines or dosages while the comparison groups comprised of placebo, non-vaccinated 313 
groups, groups that were vaccinated with other control vaccines or other dosages among HIV-314 
infected and HIV-exposed children. For case-control studies, cases were HIV-infected while 315 
controls were HIV-exposed uninfected and HIV-uninfected children.   316 
The review planned to include the following licensed vaccines: Bacillus Calmette–Guérin, 317 
hepatitis B vaccine, oral polio vaccine, inactivated polio vaccine, diphtheria-tetanus-pertussis 318 
containing vaccines, Haemophilus Influenzae type B vaccine (Hib), pneumococcal conjugate 319 
vaccine (PCV), rotavirus vaccine (RV), yellow fever vaccine and measles-containing vaccines. 320 
These vaccines were chosen because they are the frequently used childhood vaccines in 321 
countries most affected by the HIV epidemic. 322 
Exclusion criteria 323 
Studies having population aged ≥ 18 years old individuals were excluded.  We also excluded 324 
non-human studies and reviews. Most of the excluded studies reported outcomes such as level 325 
of antibodies, duplicates, reviews, studies not involving human, studies not reporting 326 
confirmed cases of vaccine-preventable diseases, reported vaccine efficacy and reported 327 
vaccine effectiveness. 328 
 329 
Outcomes 330 
The following were the outcome measures of interest: 331 
1.  Clinical and/or confirmed cases of vaccine-preventable diseases of interest. 332 
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2.          Pooled/reported vaccine efficacy. 333 
3.          Pooled/reported vaccine effectiveness. 334 
 335 
Data sources 336 
One of the authors, OOA, searched the Web of Science, Cochrane Library, MEDLINE via 337 
PubMed and Scopus databases. Reference lists from identified papers and ClinicalTrials.gov 338 
trials registry platform were also checked. Relevant WHO position papers and documents on 339 
vaccines were also scrutinised. There was no language or date restriction. 340 
Selection of studies 341 
 Two authors, OOA and DN, independently screened the search results using the abstract titles. 342 
They also independently went through the full text of potential studies to determine if the 343 
studies meet the inclusion criteria. Discrepancies in the selection process were resolved by 344 
consensus. 345 
Data extraction 346 
The two reviewers extracted data from selected articles using a pre-specified form. The extracts 347 
included information such as author, journal, year of publication, study design, country of 348 
study, participants' characteristics, intervention, comparator, type of vaccine and outcomes. 349 
Efficacy and effectiveness data were separately extracted for each vaccine group, target group 350 
(i.e. HIV-infected versus HIV-exposed / HIV-uninfected) and study type (interventional versus 351 
observational). 352 
Quality assessment 353 
The review quality assessment was guided by the use of Cochrane Collaboration’s tool for 354 
assessing the risk of bias for included trials and the use of adapted Cochrane tool for 355 
observational studies.42,43 Two authors, OOA and DN, independently assessed the 356 
methodological quality of all included studies that met the eligibility criteria. The researchers 357 
compared notes for each item and resolved discrepancies through discussion. 358 
Synthesis of data  359 
Synthesis of data was carried out using meta-analysis where applicable. Where meta-analysis 360 
was not possible, a narrative synthesis was used. We reported the dichotomous outcomes as 361 
risk ratios or odds ratio with their corresponding 95% confidence intervals (CI) while 362 
continuous outcomes were reported as mean differences.44 We reported the vaccine 363 
effectiveness with the random-effects odds ratio (OR) using the formula: (1 – OR) × 100 while 364 
vaccine efficacy was established with risk ratio (RR): (1 – RR) × 100. The efficacy and 365 
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effectiveness of each vaccine in the intervention arm was compared with that of the control 366 
arm. We also planned to use funnel-plot regression to assess publication bias if we had up to 367 
ten studies per vaccine type. RevMan statistical software was used to do all calculations, the 368 
meta-analysis and to generate the forest plot.45   369 
Sensitivity analysis 370 
The certainty of the evidence regarding primary outcomes was determined by the use of the 371 
Grades of Recommendations, Assessment, Development and Evaluation (GRADE) 372 
approach.46 The term relative effect as used in GRADE refers to either Relative risk or Odds 373 
Ratio. The risk with placebo is an assumed risk or score in a group of people who do not receive 374 
the intervention. The risk with vaccine is a corresponding risk or score in a group of people 375 
who do receive the intervention. We planned to assess substantial heterogeneity if I2 exceeded 376 
50% and the meta-analysis had up to five studies and to perform subgroup analyses using pre-377 
specified potential sources of heterogeneity such as: type of comparison (i.e. placebo or no 378 
vaccine), blinding of patients (only for trials); blinding of outcome assessors; and overall 379 
methodological quality.  380 
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Abstract 31 
Evidence-based approaches were used in making recommendations for vaccination against 32 
vaccine-preventable diseases for HIV-infected and HIV-exposed individuals but with limited 33 
substantiation. We conducted a systematic review and meta-analysis with randomised-controlled 34 
trials (RCTs), cohort and case-control studies that have efficacy and effectiveness of vaccines in 35 
HIV-infected and HIV-exposed children as outcomes. Web of Science, Cochrane Library, PubMed 36 
and Scopus databases were searched for articles. Efficacy of 9-valent pneumococcal conjugate 37 
vaccine (PCV9) against total vaccine serotype invasive pneumococcal disease was 32% in HIV-38 
infected children and 78% among HIV-uninfected children. Vaccine effectiveness of Bacillus 39 
Calmette–Guérin vaccine in preventing tuberculosis in HIV-infected children was zero compared 40 
to 59% protection in HIV-unexposed children. Likewise, HIV-uninfected children have better 41 
protection against invasive Haemophilis influenzae type b disease than the HIV-infected children. 42 
Effectiveness studies of rotavirus vaccines show that HIV-exposed uninfected children have 43 
similar protection against rotavirus gastroenteritis compared to the non-exposed children. Children 44 
who are severely immunosuppressed are poorly protected against invasive pneumococcal diseases. 45 
HIV-infected children tend to have lesser vaccine protection against vaccine-preventable diseases 46 
when compared to unexposed children. HIV-infected children who are immunocompetent are 47 
more likely to have better vaccine protection against vaccine-preventable diseases than those who 48 
are immunosuppressed. The overall quality of the observational studies was very low with very 49 
little confidence in the effect estimate. The overall quality of evidence for the RCT outcomes was 50 
mainly high. This study reveals a dearth of efficacy and effectiveness studies among HIV-infected 51 
and exposed children. 52 
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; efficacy; effectiveness 53 
 54 
 55 
 56 
 57 
Background 58 
Immunisation is an essential aspect of preventive medicine and critical in reducing morbidity and 59 
mortality attributed to vaccine-preventable diseases in children, adolescents and adults.1 The use 60 
of vaccines against various vaccine-preventable diseases is beneficial and an effective measure for 61 
protecting different age groups.2,3 The vaccination rates of children remain insufficient for vaccine-62 
preventable diseases in many developing countries with only 86% of infants vaccinated with three 63 
doses of diphtheria-tetanus-pertussis containing vaccine in 2016.4 Low vaccination uptake rate 64 
results in an increase in unvaccinated and under-vaccinated human immunodeficiency virus 65 
(HIV)-infected and HIV-exposed children who are more likely to die from preventable diseases 66 
than their immunocompetent age mates.5,6 Several care and treatment guidelines have identified 67 
vaccination as a crucial preventive strategy for people living with HIV7,8 but information on the 68 
use of certain vaccines in this population are still scanty.9  69 
Experts using evidenced-based approaches on the vaccination of immunocompromised individuals 70 
made specific recommendations for vaccination against major vaccine-preventable diseases for 71 
these patients but with limited proof.8 Research gaps were also identified by this group for future 72 
investigation. One of these gaps was that of understanding the mediators of vaccine protection, 73 
adverse effects and basic aspects of the epidemiology of various vaccine-preventable diseases.8  74 
Vaccines stimulate immunity that protects against specific disease-causing organisms. However, 75 
the effectiveness of different recommended vaccines in HIV-infected children may be reduced as 76 
a result of the decline in vaccine-induced antibodies.10 The changing pattern of some vaccine-77 
preventable diseases is poorly understood, and this changing pattern and epidemiology makes it 78 
important to better understand these diseases because of apparent resurgence and epidemics in 79 
future.11 The suboptimal uptake of vaccines in sub-Saharan Africa coupled with the high HIV 80 
burden are risk factors that may facilitate future epidemics.11,12  81 
Previous reviews on the efficacy and effectiveness of vaccines in HIV-infected and exposed 82 
children were not specific on the vaccine efficacy/effectiveness against disease outcomes and were 83 
not conducted as systematic reviews 13,14. It is paramount to evaluate the available evidence by 84 
identifying high-quality literature and investigating the reliability of key findings as they relate to 85 
the pre-licensure efficacy and post-licensure effectiveness of vaccines in HIV-infected and HIV-86 
exposed children compared to HIV unexposed children. The findings will provide the needed 87 
evidence to guide healthcare policymakers, guideline developers, vaccinologists and healthcare 88 
workers in developing improved long-term vaccination strategies for HIV-infected children. 89 
Current and reliable evidence-based data on the efficacy and effectiveness of vaccines in HIV-90 
infected and HIV-exposed children are also vital to inform a better understanding of the prevention 91 
and management of vaccine-preventable diseases in these children.  92 
This systematic review and meta-analysis summarised available data from studies which have 93 
efficacy or effectiveness of vaccines in HIV-infected and HIV-exposed children as outcomes. 94 
 95 
Results 96 
Description of included studies 97 
The flow diagram in Figure 1 shows the studies identified and selected for this review. We 98 
identified 725 publications through databases and clinical trial registry search with 479 studies 99 
after removal of duplicates. A total of 14 publications were included in this review. These 100 
publications comprise five randomised-controlled trials (RCTs),15-19 six case-control studies,20-25 101 
one cohort study26 and two cross-sectional studies27,28. Three of the included studies were 102 
publications from a particular South African trial that reported different vaccine efficacy 103 
outcomes.15,17,18 The included studies were published from 1993 to 2017.  All the included studies 104 
were conducted in sub-Saharan Africa with ten publications from South Africa, one each from 105 
Malawi, Angola and Zambia, and one multinational study conducted in Mali, Kenya and Ghana.  106 
By outcomes, three studies reported rotavirus vaccine outcomes, six studies reported on 107 
pneumococcal vaccine, one study reported on Hib vaccine, two studies on Bacillus Calmette–108 
Guérin (BCG) and two studies reported on Hepatitis B virus (HBV) vaccines (Table 1). Two 109 
studies compared vaccine strains with placebo among HIV-infected children while three studies 110 
compared vaccine strains with placebo among HIV-infected and HIV-unexposed children. Six 111 
studies compared HIV-infected children with HIV-unexposed children, while two studies 112 
compared HIV-exposed and uninfected children with HIV-unexposed children. In total, 66,220 113 
children in comparative studies were involved in the included studies. The vaccine schedule and 114 
doses for the included studies were according to various national programme except for Madhi 115 
200717 participants who were followed up for five years. Antiretroviral therapy (ART) usage 116 
varied between 22.5% and 67.0% among the HIV-infected children.  117 
Figure 1: Flow diagram of the search and selection process for this review 118 
 119 
Table 1: Characteristics of included studies 120 
 121 
 122 
Quality of evidence 123 
 124 
Risk of bias assessment of individual studies                                                                                                                            125 
Risk of bias assessment of the included studies is summarised separately for RCTs (Figure 2) 126 
and observational studies (Figure 3). All the studies except one contained at least one domain 127 
classified as high risk of bias or with no clear information.  128 
Randomised trials 129 
Only three RCTs were assessed.15,16,19 Klugman 200315 was used in assessing two other included 130 
studies17,18 since the study participants were the same for all three publications. There was 131 
insufficient information on random sequence selection in majority of the studies as shown in 132 
Figure 4. Allocation concealment, performance and detection biases were low for most of the 133 
studies. Steele 201119 had unclear risk of bias for most of the domains. Feikin 201216 had high risk 134 
of bias for reporting and other bias domains for not reporting all the pre-specified primary 135 
outcomes and having numerous limitations.  136 
 137 
 138 
Figure 2: Risk of bias summary for the included randomised-controlled trials 139 
 140 
Observational studies 141 
All the observational studies had one high or unclear risk of bias across different domains except 142 
one study.15,20,21,23-28 The reasons for the high risk of bias varied and ranged from the use of hospital 143 
control instead of community controls, imbalanced missing participant numbers and unmeasured 144 
confounders (Figure 5).  145 
 146 
 147 
 148 
  Figure 3: Risk of bias summary for the included observational studies 149 
 150 
Figure 4: Risk-of-bias graph: review authors' judgements about each risk-of-bias item presented as percentages 151 
across all included studies 152 
 153 
Figure 5: Risk of bias graph: review authors' judgements about each risk-of-bias item presented as percentages 154 
across all included studies 155 
 156 
The quality of the evidence was also evaluated using the Grades of Recommendations, 157 
Assessment, Development and Evaluation (GRADE) approach. Overall quality for the 158 
observational studies was very low with very little confidence in the effect estimate. The overall 159 
quality of evidence for the RCT outcomes was mainly high. This makes our confidence in the 160 
effect estimate to be moderate. With these results, we are confident that the true effect lies close 161 
to that of the estimate of the effect and does not require further research. See Summary of findings 162 
in Tables 2 and 3. 163 
Table 2: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-164 
uninfected children (RCTs) 165 
 166 
Table 3: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-167 
uninfected children (Observational studies) 168 
 169 
Vaccine efficacy for vaccine-preventable diseases outcomes 170 
Table 4 shows reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes 171 
in vaccinated versus non-vaccinated participants in trials for several outcomes. Vaccine efficacy 172 
of 9-valent pneumococcal conjugate vaccine (PCV9) vs. placebo in preventing first episodes of 173 
invasive pneumococcal disease was 53% (95% CI 21 - 73) among HIV-infected children and 42% 174 
(95% CI -28 - 75) among HIV-uninfected children. Efficacy of PCV9 against total vaccine 175 
serotype invasive pneumococcal disease was 32% (95% CI -14 - 60) in HIV-infected and 78% 176 
(95% CI 34 - 92) among HIV-uninfected children.  177 
There was similar response among HIV-infected children who were given RIX4414 vaccine and 178 
those given placebo for prevention of acute rotavirus diarrhoea (RR= 1.00; 95% CI 0.26 - 3.78) 179 
(Table 5). The subset of HIV-infected children in a particular trial that compared pentavalent 180 
rotavirus vaccine (PRV) and placebo showed RR of 2.81 (95% CI 0.12 - 63.83) (Table 5). 181 
Vaccine effectiveness for vaccine-preventable diseases outcomes 182 
Table 6 reports vaccine effectiveness for vaccine-preventable diseases outcomes in vaccinated 183 
versus non-vaccinated participants in observational studies for different outcomes. The pooled 184 
odds ratio (OR) of two studies on the effectiveness of HBV vaccines between HIV-infected and 185 
HIV-uninfected children was OR = 6.02 (95% CI 0.93 - 38.83; I2 = 0.00%) (Table 5; Figure 6). 186 
Vaccine effectiveness of BCG vaccine in preventing tuberculosis in HIV-infected children was 187 
zero compared to 59 %percent protection in HIV-unexposed children (Table 5). Likewise, HIV-188 
uninfected children have better protection against invasive Hib disease than the HIV-infected 189 
children (97% versus 44%). Effectiveness studies of rotavirus vaccines show that HIV-exposed 190 
uninfected children have similar protection against rotavirus gastroenteritis comparable to the non-191 
exposed children. The adjusted vaccine effectiveness of PCV13 against invasive pneumococcal 192 
disease was 78% (95% CI 46 to 91) in HIV-uninfected children, 17% (95% CI –304 - 80) in HIV-193 
infected and –104% (95% CI –1433 - 73) among HIV-infected children who were severely 194 
immunosuppressed. 195 
 196 
Figure: 6: Forest plot of comparison: Vaccine effectiveness comparing HIV-infected and HIV-uninfected - 197 
Hepatitis B vaccine, outcome: HBV/Hepatitis B vaccine 198 
 199 
Table 4: Reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes in vaccinated vs. 200 
non-vaccinated participants in randomised-controlled trials 201 
 202 
Table 5: Calculated vaccine efficacy and effectiveness for various vaccine outcomes 203 
Table 6: Reported vaccine effectiveness against vaccine-preventable diseases in observational studies 204 
Discussion 205 
The findings of this systematic review show that various routine vaccines have varying levels 206 
of protective efficacy and effectiveness against different vaccine-preventable diseases among 207 
HIV-infected and HIV-exposed children. This study demonstrates that PCV9 and 13-valent 208 
pneumococcal conjugate vaccine (PCV13) vaccines are efficacious in preventing invasive 209 
pneumococcal disease, radiologically confirmed pneumonia and severe pneumonia.15 PCV9 210 
also reduced the incidence of antibiotic-resistant invasive and vaccine serotype pneumococcal 211 
disease in both HIV-infected and uninfected children.15 However, PCV vaccines are less 212 
efficacious in preventing total vaccine serotype invasive pneumococcal disease in HIV-213 
infected children compared to HIV-uninfected children.16 Cohen et al. show that HIV-infected 214 
children have less protection against invasive pneumococcal disease when vaccinated with 215 
doses of PCV13.21 HIV-infected children with severe immunosuppression are unprotected 216 
against invasive pneumococcal disease even at higher vaccine doses.21 217 
Vaccine-efficacy studies show that RIX4414 and PRV do not have protective activities against 218 
acute rotavirus diarrhoea in HIV-infected children.16,19 The poor efficacy of PRV in children 219 
living with HIV may largely be as a result of the small sample size of the HIV-infected children 220 
subset in a Kenyan trial.16 However, Feikin et al. show that PRV efficacy against severe 221 
rotavirus gastroenteritis was 63.9% (95% CI −5.9-89.8) in a study with a large number of both 222 
HIV-infected and uninfected children in the second year of life and 83% in the first year of life. 223 
The study on RIX4414 shows that there was no significant difference in the incidence of 224 
rotavirus diarrhoea in the vaccine and placebo groups thereby deducing that the vaccine did 225 
not have any significant protective effect in HIV-infected children.17 Monovalent rotavirus 226 
vaccines provided at least 40-60% percent protection against acute rotavirus gastroenteritis in 227 
both HIV-exposed uninfected and HIV-unexposed children but the effectiveness in HIV-228 
infected children is not yet known.23,26  229 
Vaccine-effectiveness studies show that Hib conjugate vaccine provided more than 50% 230 
protection against invasive Hib disease in HIV-uninfected children when compared to HIV-231 
infected children.24 Hib conjugate vaccine has a protective effect of 83% in preventing overall 232 
invasive Hib disease in among HIV-infected children and very useful.26 A study among 233 
Zambian children shows that BCG has 59% protective effect against tuberculosis in HIV-234 
uninfected children and none in HIV-infected children.24 The findings of a case-control study 235 
among Brazilian children also allude to the fact that BCG does not protect against tuberculosis 236 
in immunodeficient HIV-infected children.20 237 
Studies have shown that most of the vaccines included in this review are safe for use in all 238 
categories of children.1,15,19,29,30 A number of reviews and safety studies on several routine 239 
vaccines among HIV-infected/exposed children and HIV-unexposed children show that there 240 
was no significant difference in these groups of children with respect to adverse events, serious 241 
adverse events and death.26-33 Most of the serious adverse events and deaths were not vaccine 242 
related. Reviews also show that immune responses to primary vaccination in HIV-infected 243 
children were less likely compared to HIV-unexposed and HIV-exposed children and may 244 
require booster doses.31-33  245 
There is a dearth of vaccine efficacy and effectiveness studies against vaccine-preventable 246 
diseases among HIV-infected and exposed children. This review shows that some efficacy 247 
studies have been done for PCV, BCG, rotavirus vaccines and Hib vaccines in HIV-infected 248 
children. There is a need to close the knowledge gap in relation to pre-licensure vaccine 249 
efficacy and post-licensure vaccine effectiveness against key vaccine-preventable diseases 250 
among these groups of children. Closing the gaps will entail conducting efficacy and 251 
effectiveness studies for several routine vaccines in HIV-infected and exposed children.13 Use 252 
of BCG vaccines in HIV-infected children can lead to disseminated tuberculosis hence it is 253 
contraindicated in immunocompromised children. It is therefore, not advisable to do a BCG 254 
vaccine-efficacy study in these children.34 BCG is safe in immunocompetent infants, however, 255 
immunocompromised infants are at high risk of developing disseminated BCG disease.35  256 
It is estimated that 1.8M children are currently with living with HIV,  most of them residing in 257 
sub-Saharan Africa.36 This region also has the highest burden for most of the vaccine–258 
preventable diseases such as tuberculosis etc.37 It is therefore essential to have the children 259 
living with HIV and those exposed to HIV be protected against vaccine-preventable diseases 260 
despite possible lower vaccine efficacy among such populations.  261 
Effectiveness research is essential and relevant for decision making by policy makers, 262 
treatment guideline researchers, vaccine development researchers and healthcare providers.38 263 
Vaccine-efficacy research is essential in making the necessary decisions to achieve the goals 264 
of the Global Health 2035 Grand Convergence.39 The World Health Organization (WHO) has 265 
already recommended many vaccines for use in immunocompromised children especially those 266 
who have had exposure to HIV, however, most of these recommendations were made without 267 
specific vaccine-efficacy and effectiveness studies conducted in this population but rather from 268 
research findings on immunocompetent children or by using safety and immunogenicity 269 
studies.1,34  Advisory Committee on Immunization Practices (ACIP) also recommended various 270 
licensed vaccines for HIV-exposed children from birth through adolescence years except for 271 
BCG.40  Knowing the vaccine efficacy and effectiveness against specific diseases will help 272 
steer guideline development and the need for better vaccines if the level of protection is low. 273 
Strengths of this systematic review and meta-analysis are the comprehensive search conducted 274 
in several databases and the inclusion of several routine vaccines. This review also compiled 275 
evidence on efficacy and effectiveness of vaccines that could be of use in HIV-infected and 276 
HIV-exposed children especially in sub-Saharan Africa. The outcomes reported and pooled for 277 
this review were based on clinical features and diagnostic methods that has not changed 278 
significantly over the last two decades and as such not a limitation for this study.  Lack of direct 279 
comparisons between HIV-infected and unexposed children with respect to various clinical 280 
cases of vaccine-preventable diseases limited straightforward grading of the evidence for 281 
clinical case outcomes.   Only seven studies could be included in the meta-analysis due to lack 282 
of data information on some clinical outcomes and reported efficacy and effectiveness as 283 
described by the authors. Most of the included papers did not relate the immune status of the 284 
children with the efficacy of the administered vaccines except for Cohen et al. 21 which shows 285 
that lesser efficacy in children with severe immunosuppression. The included studies also did 286 
not report on the time interval between vaccination and the onset of the vaccine-preventable 287 
diseases.  288 
 289 
Conclusions 290 
Efficacy and effectiveness studies on vaccination exhibit possibilities for direct and indirect 291 
protection against various vaccine-preventable diseases among HIV-infected and HIV-exposed 292 
children. HIV-infected children tend to have less protection against vaccine-preventable 293 
diseases when compared to unexposed children. HIV-infected children who are 294 
immunocompetent are more likely to have better vaccine protection against vaccine-295 
preventable diseases than the immunosuppressed ones. There is also a need to bridge the 296 
knowledge gap on vaccine efficacy and effectiveness of several routine vaccines in HIV-297 
infected and exposed children. Theis study showssuggests that only a few vaccine-efficacy and 298 
effectiveness studies have been done in HIV-infected and exposed children previously. 299 
 300 
Methods 301 
Search strategy and selection criteria 302 
This review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis 303 
Protocols (PRISMA) guideline.41 The review was registered with PROSPERO (International 304 
prospective register of systematic reviews) (CRD42018095334).  305 
 306 
Eligibility criteria 307 
 308 
Inclusion criteria 309 
 310 
We included randomised-controlled trials, cohort and case-control studies that included 311 
efficacy or effectiveness of vaccines in HIV-infected in comparison with HIV-exposed or HIV-312 
uninfected children aged ≤ 18 years. The intervention group included those with standard 313 
vaccines or dosages while the comparison groups comprised of placebo, non-vaccinated 314 
groups, groups that were vaccinated with other control vaccines or other dosages among HIV-315 
infected and HIV-exposed children. For case-control studies, cases were HIV-infected while 316 
controls were HIV-exposed uninfected and HIV-uninfected children.   317 
The review planned to include the following licensed vaccines: Bacillus Calmette–Guérin, 318 
hepatitis B vaccine, oral polio vaccine, inactivated polio vaccine, diphtheria-tetanus-pertussis 319 
containing vaccines, Haemophilus Influenzae type B vaccine (Hib), pneumococcal conjugate 320 
vaccine (PCV), rotavirus vaccine (RV), yellow fever vaccine and measles-containing vaccines. 321 
These vaccines were chosen because they are the frequently used childhood vaccines in 322 
countries most affected by the HIV epidemic. 323 
Exclusion criteria 324 
Studies having population aged ≥ 18 years old individuals were excluded.  We also excluded 325 
non-human studies and reviews. Most of the excluded studies reported outcomes such as level 326 
of antibodies, duplicates, reviews, studies not involving human, studies not reporting 327 
confirmed cases of vaccine-preventable diseases, reported vaccine efficacy and reported 328 
vaccine effectiveness. 329 
 330 
Outcomes 331 
The following were the outcome measures of interest: 332 
1.  Clinical and/or confirmed cases of vaccine-preventable diseases of interest. 333 
2.          Pooled/reported vaccine efficacy. 334 
3.          Pooled/reported vaccine effectiveness. 335 
 336 
Data sources 337 
One of the authors, OOA, searched the Web of Science, Cochrane Library, MEDLINE via 338 
PubMed and Scopus databases. Reference lists from identified papers and ClinicalTrials.gov 339 
trials registry platform were also checked. Relevant WHO position papers and documents on 340 
vaccines were also scrutinised. There was no language or date restriction. 341 
Selection of studies 342 
 Two authors, OOA and DN, independently screened the search results using the abstract titles. 343 
They also independently went through the full text of potential studies to determine if the 344 
studies meet the inclusion criteria. Discrepancies in the selection process were resolved by 345 
consensus. 346 
Data extraction 347 
The two reviewers extracted data from selected articles using a pre-specified form. The extracts 348 
included information such as author, journal, year of publication, study design, country of 349 
study, participants' characteristics, intervention, comparator, type of vaccine and outcomes. 350 
Efficacy and effectiveness data were separately extracted for each vaccine group, target group 351 
(i.e. HIV-infected versus HIV-exposed / HIV-uninfected) and study type (interventional versus 352 
observational). 353 
Quality assessment 354 
The review quality assessment was guided by the use of Cochrane Collaboration’s tool for 355 
assessing the risk of bias for included trials and the use of adapted Cochrane tool for 356 
observational studies.42,43 Two authors, OOA and DN, independently assessed the 357 
methodological quality of all included studies that met the eligibility criteria. The researchers 358 
compared notes for each item and resolved discrepancies through discussion. 359 
Synthesis of data  360 
Synthesis of data was carried out using meta-analysis where applicable. Where meta-analysis 361 
was not possible, a narrative synthesis was used. We reported the dichotomous outcomes as 362 
risk ratios or odds ratio with their corresponding 95% confidence intervals (CI) while 363 
continuous outcomes were reported as mean differences.44 We reported the vaccine 364 
effectiveness with the random-effects odds ratio (OR) using the formula: (1 – OR) × 100 while 365 
vaccine efficacy was established with risk ratio (RR): (1 – RR) × 100. The efficacy and 366 
effectiveness of each vaccine in the intervention arm was compared with that of the control 367 
arm. We also planned to use funnel-plot regression to assess publication bias if we had up to 368 
ten studies per vaccine type. RevMan statistical software was used to do all calculations, the 369 
meta-analysis and to generate the forest plot.45   370 
Sensitivity analysis 371 
The certainty of the evidence regarding primary outcomes was determined by the use of the 372 
Grades of Recommendations, Assessment, Development and Evaluation (GRADE) 373 
approach.46 The term relative effect as used in GRADE refers to either Relative risk or Odds 374 
Ratio. The risk with placebo is an assumed risk or score in a group of people who do not receive 375 
the intervention. The risk with vaccine is a corresponding risk or score in a group of people 376 
who do receive the intervention. We planned to assess substantial heterogeneity if I2 exceeded 377 
50% and the meta-analysis had up to five studies and to perform subgroup analyses using pre-378 
specified potential sources of heterogeneity such as: type of comparison (i.e. placebo or no 379 
vaccine), blinding of patients (only for trials); blinding of outcome assessors; and overall 380 
methodological quality.  381 
 382 
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Table 1: Characteristics of included studies 
Participants Intervention Control 
1st 
Author 
& Year 
 
Study 
period 
 
Study 
design 
Study 
country 
Sample size 
(n=) 
Participant 
age range 
HIV 
status  
% on 
ART 
CD4 % or 
count 
Age 
(median or 
mean) 
Vaccine 
strain 
HIV 
status  
% on ART CD4 % 
or 
count 
Age 
(median 
or mean) 
Vaccine strain 
Beghin 
201727 
2014 Cross- 
sectional 
study 
South 
Africa 
291 5-15y HI NR NR 9.1y  HBV  HU - - 9.0y  HBV 
Cohen 
201721 
2012-
2014 
Case- 
Control 
South 
Africa 
1716 ≥6w HI 58% - 48-53w PCV13 HU - - 36-37w PCV13 
Bar-Zeev 
201625 
1997-
2007 
Case-
control 
Malawi 919 <5y HEU - - NA RV HU - - NA RV 
Van-
Dunem 
201522 
 
2005-
2006 
 
Case-
control 
 
Angola 902 
 
18m - 13y 
 
HI 67% NR 4.83y  
 
BCG 
Connaught 
 
HI 61% NR 3.50y  
 
- 
Cohen 
201419 
2010-
2012 
Case- 
Control 
South 
Africa 
1395 ≥8w HI 46% NR 52-54w PCV7 HU - - 38-39w PCV7 
Groome 
201423 
2010-
2012 
Case-
control 
South 
Africa 
1195 18w-23m HEU - - 9m Monovalent 
human RV 
HU - - 10 m Monovalent 
human RV 
Feikin 
201216 
2007-
2009 
RCT Kenya, 
Ghana, 
Mali 
29 4-12w HI NR NR 17.1w PRV HI NR NR 17.0 Placebo 
Steele 
201119 
2005-
2008 
RCT South 
Africa 
100 6-10w (at 
dose 1) 
HI 62% 2074 7w RIX4414  HI 52% 2022 7w Placebo 
Simani 
200828 
2003-
2004 
Cross- 
sectional 
study 
South 
Africa 
303 5-24m 
 
HI  NR NR 8.7m HBV 
 
 
HU - - 11.9m HBV 
Madhi 
200717 
2001 -
2005 
Post RCT  South 
Africa 
 39836 5.57-5.80y HI 22.5% 493; 627 5.80y; 
5.68y 
PCV9 HU - - 5.68y; 
5.57y 
Placebo 
Madhi 
200518 
1998 - 
2001 
RCT South 
Africa 
 39836 28-84d HI NR NR NA PCV9 HU - -   Placebo 
Klugman 
200315 
1998 - 
2001 
RCT South 
Africa 
39836 28-84d HI NR NR NA PCV9 HU - - 7w Placebo 
Madhi 
200226 
1997-
2000 
Cohort South 
Africa 
19267 <1y HI NR NR NR HibCV  HU - - NR HibCV 
Bhat 
199324 
 
1991 
 
Case-
control 
 
Zambia 270 1m-14y HI NR NR NR BCG HU NR NR NR BCG 
HI - HIV-infected;   HEU - HIV-exposed uninfected; HU - HIV-uninfected; NR- not reported; m- month; w – week;  d- day; y- year; RCT – randomized controlled trial; HBV – Hepatitis B vaccine; HibCV- haemophilus 
influenzae b conjugate vaccine; PCV7 – 7-valent pneumococcal conjugate vaccine; PCV9 – 9-valent pneumococcal conjugate vaccine; PCV13 – 13-valent pneumococcal conjugate vaccine; BCG - Bacillus Calmette–
Guérin; PRV – pentavalent rotavirus 
Table 1
Table 2: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-
uninfected children (RCTs) 
Patient or population: HIV-infected, HIV-exposed and HIV-uninfected children  
Intervention: Vaccines  
Comparison: Placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the evidence 
(GRADE)  
 Risk with 
placebo 
Risk with vaccines 
HI/PRV/RVGE  
0 per 1,000  
0 per 1,000 
(0 to 0)  
RR 2.81 
(0.12 to 63.83)  
29 
(1 RCT)  
⨁⨁◯◯ 
LOW a 
HI/RIX4414/RVGE  
80 per 1,000  
80 per 1,000 
(21 to 270)  
RR 1.00 
(0.26 to 3.78)  
100 
(1 RCT)  
⨁⨁⨁◯ 
MODERATE a 
HI/PCV9/severe 
pneumonia  
280 per 1,000  
233 per 1,000 
(205 to 266)  
RR 0.83 
(0.73 to 0.95)  
2577 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HU/PCV9/severe 
pneumonia  
36 per 1,000  
32 per 1,000 
(28 to 36)  
RR 0.89 
(0.80 to 1.00)  
37259 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HI/PCV9/Total IPD  
26 per 1,000  
18 per 1,000 
(11 to 30)  
RR 0.68 
(0.40 to 1.14)  
2577 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HU/PCV9/Total IPD  
1 per 1,000  
0 per 1,000 
(0 to 0)  
not estimable  37259 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio; HI: HIV-infected; PRV: Pentavalent rotavirus vaccine; RVGE: Rotavirus gastroenteritis; HU: HIV-uninfected; PCV9: 
9-valent pneumococcal conjugate vaccine; IPD: Invasive pneumococcal disease 
Explanation:  a. A wide confidence interval of the estimate  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
 
Table 2 revised
 Table 3: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-
uninfected children (Observational studies) 
Patient or population: HIV-infected, HIV-exposed and HIV-uninfected children 
Intervention: Vaccine  
Comparison: Placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the evidence 
(GRADE)  
 Risk with placebo Risk with vaccine 
HBV/Hepatitis B 
vaccine  3 per 1,000  
18 per 1,000 
(3 to 103)  
OR 6.02 
(0.93 to 38.83)  
594 
(2 observational 
studies)  
⨁◯◯◯ 
VERY LOW a,b 
HI/BCG/Tuberculosis  Low  OR 1.00 
(0.22 to 4.56)  
36 cases 18 controls 
(1 observational 
study)  
⨁◯◯◯ 
VERY LOW b,c 
0 per 1,000  
0 per 1,000 
(0 to 0)  
HU/BCG/Tuberculosis  Low  OR 0.41 
(0.18 to 0.92)  
60 cases 116 controls 
(1 observational 
study)  
⨁◯◯◯ 
VERY LOW b,c 
0 per 1,000  
0 per 1,000 
(0 to 0)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval; OR: Odds ratio; BCG: Bacillus Calmette–Guérin 
Explanations: a. Confounders were not taken into account and unclear about the selection of study participants; b. A wide confidence interval around the 
estimate of the effects; c. Confounders not taken into account  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Table 3 revised
Table 4: Reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes in vaccinated vs. non-vaccinated participants in randomised-controlled 
trials 
Study ID (year) Doses Experimental recipients/vaccine Control recipients/vaccine  Vaccine efficacy (%) Disease of interest 
Klugman 200315 3 HI/PCV9 HI/placebo 53 (21 to 73) First episodes of invasive pneumococcal 
disease Klugman 200315 3 HU/PCV9 HU/placebo 42 (-28 to 75) 
Klugman 200315 3 HI/PCV9 HI/placebo 13 (-7 to 29) First episodes of radiologically confirmed 
pneumonia Klugman 200315 3 HU/PCV9 HU/placebo 20 (2 to 35) 
Madhi 200517 3 HI/PCV9 HI/placebo 17 (5, 27) WHO-defined severe pneumonia 
Madhi 200517 3 HU/PCV9 HU/placebo 11 (1, 20) 
Madhi 200718 3 HI/PCV9 HI/placebo 32 ( -14, 60) Total vaccine serotype invasive 
pneumococcal disease Madhi 200718 3 HU/PCV9 HU/placebo 78 (34, 92) 
Steele 201119 3 HI/ RIX4414 HI/placebo 0 (-278, 74) Acute rotavirus diarrhoea 
Feikin 201216 3 HI/PRV HI/placebo -181 (-6283, 88) 
 
 
Table 4
Table 5: Calculated vaccine efficacy and effectiveness for various vaccine outcomes 
Outcomes  
Number 
of 
studies Experimental group Control group Relative effects 
Study 
references 
Hepatitis B virus infection 2 HI/HBV HU/HBV OR = 6.02 (0.93, 38.83) 27,28 
Rotavirus gastroenteritis 1 HI/PRV HI/Placebo RR = 2.81 (0.12, 63.83) 16 
Rotavirus gastroenteritis 1 HI/RIX4414 HI/Placebo RR = 1.00 (0.26, 3.78) 19 
Severe pneumonia 1 HI/PCV9 HI/Placebo RR = 0.83 (0.73, 0.95) 17 
Severe pneumonia 1 HU/PCV9 HU/Placebo RR = 0.89 (0.80, 1.00) 17 
Total Invasive Pneumococcal Disease 1 HI/PCV9 HI/Placebo RR = 0.68 (0.40, 1.14) 18 
Total Invasive Pneumococcal Disease 1 HU/PCV9 HU/Placebo RR = 0.22 (0.08, 0.66) 18 
Tuberculosis 1 HI/BCG HI/Unvaccinated OR = 1.00 (0.22, 4.56) 24 
Tuberculosis 1 HU/BCG HU/Unvaccinated OR = 0.41 (0.18, 0.92) 24 
           BCG- Bacillus Calmette–Guérin vaccine; HI- HIV-infected; HU- HIV-uninfected; HBV – Hepatitis B virus; PCV – pneumococcal conjugate vaccine; PRV- pentavalent rotavirus;  
             OR- odds ratio; RR- risk ratio 
 
Table 5
Table 6: Reported vaccine effectiveness against vaccine-preventable diseases in observational studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID (year) Vaccine type Doses HIV status 
Vaccine effectiveness 
(%) 
Adjusted vaccine 
effectiveness (%) Disease of interest 
Bhat (1993)24 
BCG 
1 
 
HI 0 (−360 to 78) 
  
Tuberculosis 1 
 
HU 59 (8 to 82) 
Madhi  (2002)26 
HibCV 
3 
 
HI 43.9 ( 76.1 to 82.1) 
 
Invasive Hib disease 3 
 
HU 96.5 (74.4 to 99.5) 
 
 
 
Groome (2014)23 
Monovalent RV  2 HEU   58% (16 to 79) Acute rotavirus diarrhea 
2 HU   52% (23 to 70) 
Cohen (2014)20 
PCV7 
≥3 HI 43 (−108 to 85)  
57 (−371 to 96) 
Invasive pneumococcal 
disease 
≥3 HU 57 (−100 to 91) 
90 (14 to 99) 
 
Van-Dunem (2015)22 
BCG Connaught 
1 HI 8 (−26 to 32) 
30 (−75 to 72) 
Tuberculosis 
Bar-Zeev (2016)25 
Monovalent RV 2 HEU   42.2% (−106.9 - 83.8) Acute rotavirus diarrhea 
2 
HU 
 60.5% (13.3–82.0) 
Cohen (2017)21 
 PCV13 
≥2  HI (overall) 26% (–98 to 72)  
17% (–304 to 80) 
Invasive pneumococcal 
disease 
≥2  
HI with severe 
immunosuppression –42% (–723 to 76) 
 –104% (–1433 to 73) 
≥2  
HI with no severe 
immunosuppression 75% (–31 to 95)  
66% (–94 to 94) 
≥2  HU (overall) 83% (61 to 92)  
78% (46 to 91) 
≥2  HEU  91% (60 to 98)  
87% (38 to 97) 
Table 6
